Moderna, Pfizer Stocks Fall as Omicron Covid Wave Subsides in U.S.

  • 📰 nbcchicago
  • ⏱ Reading Time:
  • 65 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 29%
  • Publisher: 51%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Moderna dropped more than 12%, the biggest decline in the S&P 500 as of Monday afternoon.

available as of Feb. 8, down from a December high of more than 1.7 million shots per day and peak levels of nearly 3.5 million shots per day in April.

The Food and Drug Administration on Friday delayed plans to fast-track authorization of the Pfizer and BioNTech's Covid vaccine for children under 5-years-old. The FDA has originally planned to authorize the first two-doses of what will ultimately be a three-dose vaccine as soon as this month. However, Pfizer and the FDA said they now plan to wait until data is submitted on the third dose in April.

Pfizer and BioNTech are also developing a Covid vaccine that targets the omicron variant. CEO Albert Bourla has said the omicron shot will be ready in March, though its unclear whether a new vaccine will be needed if cases continue to decline. Moderna has also started clinical trials on an omicron-specific booster shot.

Novavax's vaccine has not received FDA authorization yet. Its unclear how much demand there will be in the U.S. for the company's vaccine should the pandemic continue to improve after Novavax receives the regulatory green light. Moderna CEO Stephane Bancel also sold 19,000 company shares last week, totaling $2.9 million and deleted his Twitter account after two years of inactivity, raising questions on the social media platform. Bancel sells the same amount of shares on a weekly basis, according to securities filings.

 

コメントありがとうございます。コメントは審査後に公開されます。

Hell they ALREADY got their GREED at the start..

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 545. in JP

日本 最新ニュース, 日本 見出し